Special Issue

Drug Candidates for the Treatment of Atopic Dermatitis

Message from the Guest Editor

Atopic dermatitis (AD) is an immune-mediated skin disease influenced by immune system imbalance, genetic defects, and environmental conditions. Several strategies to conquer AD have been widely used. Since dry environments surrounding the skin barrier exacerbate AD manifestations, the treatment of AD focuses on how to maintain the moisture content of the skin barrier. Although steroids are also widely used for attenuating AD symptoms over a short period of time, a variety of studies have demonstrated severe disadvantages of steroid use when administered over a long time. Recent approaches for AD treatment have moved to the identification of potent candidates from naturally derived compounds due to their safety in longterm use and outstanding efficacy. A number of studies have shown that compounds discovered from natural products control the activity of immune cells for people with AD. This Special Issue aims to collect reviews that consider the current state of the art and future prospects in the field of atopic dermatitis, as well as original research articles reflecting.

Guest Editor

Dr. Hyun-Su Lee

Department of Physiology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea

Deadline for manuscript submissions

closed (25 January 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/158699

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

